Relationship of oxidative stress and endothelial dysfunction in sleep apnoea Source: Eur Respir J 2011; 37: 873-879 Year: 2011
Increased upper airway cytokines and oxidative stress in severe obstructive sleep apnoea Source: Eur Respir J 2011; 37: 89-97 Year: 2011
Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea Source: Eur Respir J 2009; 33: 793-796 Year: 2009
CPAP decreases plasma levels of soluble tumour necrosis factor-α receptor 1 in obstructive sleep apnoea Source: Eur Respir J 2008; 32: 1009-1015 Year: 2008
Effect and significance of continuous positive airway pressure treatment on vascular endothelial function in patients with obstructive sleep apnoea syndrome Source: Annual Congress 2003 - Systematic inflammation and metabolic disorders in sleep related breathing disorders Year: 2003
Association between lipid peroxidation and inflammation in obstructive sleep apnoea Source: Eur Respir J 2006; 28: 378-385 Year: 2006
Local airway inflammation in obstructive sleep apnoea: the role of leptin Source: Eur Respir J 2006; 28: Suppl. 50, 645s Year: 2006
Effects of continuous positive airway pressure on arterial stiffness and oxidative stress in patients with obstructive sleep apnoea Source: International Congress 2016 – New insights into noninvasive ventilation: between the dream and reality Year: 2016
Early changes in blood pressure, vascular and heart function in obstructive sleep apnoea (OSA). Impact of treatment Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
Mechanisms and assessment of vascular damage in obstructive sleep apnoea Source: Annual Congress 2013 –Yernault Lecture “Obstructive sleep apnoea as a model of systemic disease” followed by “Vascular tree and obstructive sleep apnoea” Year: 2013
Carotid body inflammation and cardiorespiratory alterations in intermittent hypoxia Source: Eur Respir J 2012; 39: 1492-1500 Year: 2012
Sleep apnoea, hypertension and vascular disease: where are we now? Source: Eur Respir Rev 2007; 16: 169-182 Year: 2007
The vascular micromilieu in obstructive sleep apnoea Source: Eur Respir J 2005; 25: 780-782 Year: 2005
Hypoxic stress in obstructive sleep apnea syndrome (OSAS) activates invasive ability of monocytes Source: Eur Respir J 2005; 26: Suppl. 49, 354s Year: 2005
Influence of continuous positive airway pressure therapy on endothelial function and blood pressure in patients with arterial hypertension and obstructive sleep apnoea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 814s Year: 2006
Catecholamines and obstructive sleep apnea (OSA) severity: response to positive airway pressure (PAP) therapy Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea Year: 2009
Microparticles and vascular dysfunction in obstructive sleep apnoea Source: Eur Respir J 2014; 44: 207-216 Year: 2014
Signalling pathways in intermittent hypoxia and in obstructive sleep apnoea (OSA) Source: Annual Congress 2007 - Cardiovascular and metabolic consequences of obstructive sleep apnoea: early changes, biomarkers and impact of treatment Year: 2007
Metabolic syndrome, systemic inflammation and oxidative stress in patients with severe obstructive sleep apnea: effects of CPAP Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea Year: 2008
Sympathetic activity is reduced by nCPAP in hypertensive obstructive sleep apnoea patients Source: Eur Respir J 2004; 23: 255-262 Year: 2004